The US Food and Drug Administration (FDA) has approved Yeztugo (lenacapavir) for the prevention of HIV, the Gilead Sciences website reported.
Yeztugo is the first pre-exposure prophylaxis drug that is administered every six months.
The drug prevents the replication of the virus by blocking the formation of its protective shell.
Unlike oral HIV drugs, the injectable form has a longer effect due to the slow release of the active substance.
Patients no longer need to take pills every day.
The drug showed 100% effectiveness in a clinical trial.